Tenax CEO exercises options for 8,719 shares

Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026 to acquire 8,719 common shares, including 8,500 shares at $5.94 per share and 219 shares at $3.549 per share.

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026 to acquire 8,719 common shares, including 8,500 shares at $5.94 per share and 219 shares at $3.549 per share. The aggregate exercise price for these options was paid in cash.

After the exercises, he directly owned 11,324 and 2,824 common shares in the reported accounts and continued to hold stock options covering 1,400,000 shares at a $5.89 exercise price and 450,000 shares at a $13.30 exercise price, with vesting schedules extending over several years and expirations in 2035 and 2036.

Insider Trade Summary

8,719 shares exercised/converted

Exercise 8 txns

Insider Giordano Christopher Thomas

Role CEO

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F2	219	$0.00	$0.00
Exercise	Stock Option (right to buy)	8,500	$0.00	$0.00
Exercise	Common Stock F1	219	$3.549	$777.23
Exercise	Common Stock F1	8,500	$5.94	$50K
holding	Stock Option (right to buy) F3	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F5	--	--	--
holding	Stock Option (right to buy) F6	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 3,092,000 contracts for 1,850,282 underlying shares (Direct); Common Stock — 11,324 shares (Direct)

Footnotes (6)

1. F1. The aggregate exercise price was paid in cash.
2. F2. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.
3. F3. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
4. F4. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
5. F5. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
6. F6. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.

Key Figures

Shares acquired via option exercise: 8,719 shares Exercise price per share: $5.94 Exercise price per share: $3.549 +4 more

7 metrics

Shares acquired via option exercise 8,719 shares Total common shares acquired through option exercises on July 13, 2026

Exercise price per share $5.94 Exercise price for 8,500-share stock option exercised into common stock

Exercise price per share $3.549 Exercise price for 219-share stock option exercised into common stock

Direct common shares held 11,324 shares Direct common shares held after one of the exercise-related transactions

Direct common shares held 2,824 shares Direct common shares held after the second exercise-related transaction

Unexercised option position 1,400,000 underlying shares Stock option on 1,400,000 shares at $5.89, expiring May 16, 2035

Unexercised option position 450,000 underlying shares Stock option on 450,000 shares at $13.30, expiring January 9, 2036

Key Terms

Stock Option (right to buy), exercise price, vest and become exercisable, aggregate exercise price

4 terms

Stock Option (right to buy) financial

"security_title shows Stock Option (right to buy) for derivative holdings"

exercise price financial

"conversion_or_exercise_price fields list the option exercise price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"Footnotes describe when options vest and become exercisable over several years"

aggregate exercise price financial

"A footnote states the aggregate exercise price was paid in cash"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Tenax Therapeutics (TENX) report for its CEO?

Tenax Therapeutics reported that CEO Christopher Thomas Giordano exercised stock options on July 13, 2026 to acquire 8,719 common shares. These were derivative exercises of existing options rather than open-market stock purchases.

How many TENX shares did the CEO acquire and at what exercise prices?

The CEO acquired 8,719 common shares through option exercises: 8,500 shares at an exercise price of $5.94 per share and 219 shares at an exercise price of $3.549 per share, all on July 13, 2026.

How were the TENX option exercises by the CEO paid for?

According to the report’s footnotes, the aggregate exercise price was paid in cash for the options exercised by the CEO. This indicates the transactions were cash-paid exercises rather than net or cashless exercises using previously held shares.

What are the CEO’s direct TENX common share holdings after these transactions?

Following the reported option exercises, the CEO directly held 11,324 common shares in one reported account and 2,824 common shares in another direct holding line. These figures represent his post-transaction direct ownership positions disclosed in the report.

What unexercised TENX stock options does the CEO still hold?

The CEO continues to hold stock options on 1,400,000 shares at a $5.89 exercise price and 450,000 shares at a $13.30 exercise price, plus smaller grants of 157 and 125 underlying shares at higher exercise prices, with expirations ranging from 2031 to 2036.

How do the CEO’s TENX stock options vest over time?

Footnotes state several option awards vest 25% on a specified date and 25% annually1/36 of remaining shares monthly

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/14/2026 - 07:30 PM Accepted by SEC EDGAR 07/14/2026 - 07:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giordano Christopher Thomas

(Last) (First) (Middle)

101 GLEN LENNOX DRIVE, SUITE 300

(Street)

CHAPEL HILL NORTH CAROLINA 27517

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TENAX THERAPEUTICS, INC. [ TENX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/13/2026		M		219	A	$3.549(1)	2,824	D
Common Stock	07/13/2026		M		8,500	A	$5.94(1)	11,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.549	07/13/2026		M			219	(2)	05/17/2034	Common Stock	219	$0	218	D
Stock Option (right to buy)	$5.94	07/13/2026		M			8,500	12/10/2025	12/10/2034	Common Stock	8,500	$0	1,241,500	D
Stock Option (right to buy)	$13.3							(3)	01/09/2036	Common Stock	450,000		450,000	D
Stock Option (right to buy)	$5.89							(4)	05/16/2035	Common Stock	1,400,000		1,400,000	D
Stock Option (right to buy)	$992							(5)	06/09/2032	Common Stock	125		125	D
Stock Option (right to buy)	$3,152							(6)	07/06/2031	Common Stock	157		157	D

Explanation of Responses:

1. The aggregate exercise price was paid in cash.

2. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027, and May 17, 2028, subject to the Reporting Person's continued employment.

3. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on January 9, 2027, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

4. The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.

5. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.

6. The options vested and became exercisable as follows: 25% of the underlying shares of common stock vested and became exercisable on each of July 6, 2022, July 6, 2023, July 6, 2024, and July 6, 2025, subject to the Reporting Person's continued employment.

	/s/ S. Halle Vakani, as Attorney-in-Fact	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)